Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia
Closed
This trial is comparing venetoclax and azacitidine with azacitidine for acute myeloid leukaemia (AML). In this trial, the team are looking at having azacitidine as a tablet.
It is for people who have had chemotherapy and their leukaemia went away completely. This is called remission. It means there are no leukaemia cells in your blood or
Recruitment start: 6 October 2020
Recruitment end: 10 March 2023
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Richard Dillon
AbbVie
Last reviewed: 1 December 2023
CRUK internal database number: 16801